Article

The future of customer engagement in biopharma: thinking beyond CRM

Adapting business strategies in response to evolving consumer preferences

The biopharma landscape is ripe with opportunities for those seeking an edge over competition and a say in the future of customer engagement. What’s needed now is action, and action begins with assessment. What future customer engagement models are “best fit” for a given portfolio? To capability needs? The ability to win in this emerging future lies in the answers.

Understanding the case for change

Why so much change? And why now? It’s partially the emergence from COVID-19. The pandemic accelerated a shift in commercial business models and customer expectations. Customers expect different things and have different preferences: they demand personalization, digital ways of engagement, trust, data privacy and product innovation.

Not only are customer expectations changing, but many biopharma companies face a shift in their portfolios, from blockbuster, mass market medicines to targeted, specialty therapeutics. This shift in portfolio composition requires biopharma to think differently.

 

There is a pronounced portfolio shift toward targeted, specialty therapeutics

 

Lastly, there is a technology change wave on the horizon. New opportunities created by artificial intelligence (AI) and other emerging tech coupled with Salesforce preparing to introduce new market solutions are leading many biopharma companies down the path: “what technology do we need to be successful?”

Now is the time for companies to understand their portfolio, customer shifts and ultimately, what that means for customer engagement. Doing nothing is not an option.

 

Your tailored customer engagement strategy begins with evaluating the:

  • Therapeutic area archetypes prominent in your future state portfolio
  • Customer types you will interact and engage with (patients, consumers, institutions, providers, payers, etc.)
  • Customer type key needs and their desired experiences
  • Capabilities that could help simplify collaboration and accelerate responsiveness
  • Steps to help companies bridge silos and unite to deliver this experience
  • Role technology and operations can have in bringing these capabilities to life

Customer engagement models of the future

We conducted primary market research interviews with key commercial business and digital leaders across the industry. We spoke with individuals across the Americas, Europe, and Asia. And we looked outside of biopharma for inspiration. The result? Themes and insights for understanding what customer engagement might look like in the future. Combined with our knowledge and foresight into the industry, we have identified a foundational set of models that will define the future of customer engagement for biopharma:

Learn where—and how—to play

Navigate the shift to thrive in the future of biopharma

It’s important not to react and jump into technology solutions and choices. Before embarking on a multi-year, multi-million-dollar technology initiative, pause, realign, and use this as an opportunity to define the vision and ways to better engage with and meet the needs of your customers and stakeholders. This vision should then inform your technology solutions and choices, not the other way around.

Biopharma organizations need a clear vision for their journey forward. Move ahead by:

  • Defining your future customer engagement vision. Think holistically. Consider commercial and medical engagement functions and geography when determining the technological evolution of your engagement model.
  • Determining and prioritizing business capabilities. Some customers have unique engagement needs. Align those needs to your goals to determine your capabilities and which technologies can help.
  • Evaluating application and platform architectures. Leverage current technology by selecting the product and platform strategy that offers relevant new capabilities and helps you reach your business objectives.

Methodology
Our insights were gained through various stakeholder interviews, including with C-suite and senior commercial and digital leaders across the industry. Our focus was on the Americas, Europe, and Asia.

Get in touch

Dave Rosner
Principal | Deloitte Consulting LLP
drosner@deloitte.com
+1 215 977 7570

Ryan Myers
Principal | Deloitte Consulting LLP
rmyers@deloitte.com
+1 215 789 2755

 

 
       

Kelcey Shanahan
Senior Manager | Deloitte Consulting LLP
kshanahan@deloitte.com
+1 617 960 8482

Amith Mohan
Senior Manager | Deloitte Consulting LLP
amimohan@deloitte.com
+1 201 753 1877

 

 
       

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Did you find this useful?